BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Friedreich Ataxia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Friedreich Ataxia\, f
 rom ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05515536-8966@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Vatiquinone (PTC743): Phase 3 readout est. (NCT05515536)
DESCRIPTION:Vatiquinone (PTC743)\, phase 3\, Friedreich Ataxia.\nStudy: A S
 tudy to Assess the Safety and Efficacy of Vatiquinone in Participants With
  Friedreich Ataxia\nEstimated primary completion: 31 December 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/vatiquinone-ptc743#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT05515536
URL:https://assetmemo.bio/drug/vatiquinone-ptc743#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07681713-8966@assetmemo.bio
DTSTAMP:20261121T004950Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Vatiquinone (PTC743): Phase 3 readout est. (NCT07681713)
DESCRIPTION:Vatiquinone (PTC743)\, phase 3\, Friedreich Ataxia.\nStudy: Lon
 g-Term Efficacy Study of Vatiquinone for the Treatment of Friedreich's Ata
 xia (FA)\nEstimated primary completion: 15 March 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/vatiquinone-ptc743#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07681713
URL:https://assetmemo.bio/drug/vatiquinone-ptc743#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
